Medpace Q3 Earnings Call Highlights

Medpace NASDAQ: MEDP reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win rates.

MarketBeat • 10 hours ago

Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript

Medpace Holdings, Inc. ( MEDP ) Q3 2026 Earnings Call October 22, 2026 9:00 AM EDT Company Participants David Ruhe - Associate Director of Financial Planning & Analysis August Troendle - CEO, President & Chairman Kevin Brady - CFO & Treasurer Conference Call Participants Michael Cherny - Leerink Partners LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Tucker Remmers - UBS Investment Bank, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Ryan Halsted - RBC Capital Markets, Research Division David Windley - Jefferies LLC, Research Division Christine Rains - William Blair & Company L.L.C., Research Division Eric Coldwell - Robert W.

Seeking Alpha • 9 hours ago

Medpace Slips Despite Third-Quarter Beat, Solid Earnings Outlook

Medpace stock slipped late Wednesday despite beating third-quarter forecasts and issuing an above-Street view for 2026 earnings.

Investors Business Daily • Oct 21, 2026

Medpace Holdings, Inc. Reports Third Quarter 2026 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025. Backlog as of September 30.

Business Wire • Oct 21, 2026

Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates

Medpace (MEDP) came out with quarterly earnings of $4.84 per share, beating the Zacks Consensus Estimate of $4.45 per share. This compares to earnings of $3.86 per share a year ago.

Zacks Investment Research • Oct 21, 2026

CON vs. MEDP: Which Stock Should Value Investors Buy Now?

Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Oct 14, 2026

Medpace (MEDP) Dips More Than Broader Market: What You Should Know

In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.

Zacks Investment Research • Oct 13, 2026

Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One

Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.

Seeking Alpha • Oct 13, 2026

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.

Zacks Investment Research • Oct 6, 2026

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.

Zacks Investment Research • Sep 29, 2026